Insurers often place specialty drugs in the highest tiers of patient cost-sharing, making it difficult for patients with debilitating conditions to afford treatment. The increasing use of such drug tiers and other cost-control efforts is driven by a growing number of high-priced treatments for those diseases, but lawmakers are debating ways to limit the cost to consumers.